Harish Manwani
Known title: DirectorCIK: 0001527726
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
RBC cuts Whirlpool target to $22 on 2027 risks. RBC Capital lowered its price target for Whirlpool to $22 and maintained an Underperform rating, citing risks in the 2027 outlook. This move coincides with a broader decline in building product stocks and a recent acquisition by Asurion of appliance insurer Domestic & General. The stock is currently trading near its 52-week low, reflecting significant pressure on the company's valuation.
Transaction History
| GILD | ▲ Buy | Grant | 1,146 | $0 | 4/30/2026 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 224 | $29K | 4/30/2026 | View on chart |
| GILD | ▲ Buy | Grant | 1,516 | $0 | 5/7/2025 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 296 | $29K | 5/7/2025 | View on chart |
| WHR | ▲ Buy | Grant | 2,014 | $0 | 4/15/2025 | View on chart |
| WHR | ▼ Sell | Tax Withholding | 393 | $31K | 4/15/2025 | View on chart |
| GILD | ▲ Buy | Grant | 2,310 | $0 | 5/8/2024 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 451 | $29K | 5/8/2024 | View on chart |
| WHR | ▼ Sell | Tax Withholding | 278 | $29K | 4/16/2024 | View on chart |
| WHR | ▲ Buy | Grant | 1,421 | $0 | 4/16/2024 | View on chart |
| GILD | ▲ Buy | Grant | 1,887 | $0 | 5/3/2023 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 368 | $29K | 5/3/2023 | View on chart |
| WHR | ▲ Buy | Grant | 1,074 | $0 | 4/18/2023 | View on chart |
| WHR | ▼ Sell | Tax Withholding | 210 | $0 | 4/18/2023 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 477 | $29K | 5/5/2022 | View on chart |
| GILD | ▲ Buy | Grant | 2,444 | $0 | 5/5/2022 | View on chart |
| GILD | ▲ Buy | Option Exercise | 2,223 | — | 5/3/2022 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 349 | $21K | 5/3/2022 | View on chart |
| WHR | ▼ Sell | Tax Withholding | 128 | $0 | 4/19/2022 | View on chart |
| WHR | ▲ Buy | Grant | 849 | $0 | 4/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Gilead Signs $1.9B Deal With Vir For T-Cell Engagers
Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.
Gilead Signs $1.9B Deal With Vir For T-Cell Engagers. Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.